Estradiol
- Generic Name
- Estradiol
- Brand Names
- Activella 1/0.5 28 Day, Activelle, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Etyqa 0.5/0.1 28 Day, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24O2
- CAS Number
- 50-28-2
- Unique Ingredient Identifier
- 4TI98Z838E
- Background
Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays,...
- Indication
Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (...
- Associated Conditions
- Atrophic Vaginitis, Breast Cancer, Breast engorgement caused by Postpartum state, Heavy Menstrual Bleeding, Hypogonadism female, Kraurosis Vulvae, Metastatic Breast Cancer, Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure (POF), Prostate Cancer, Severe Pain, Urogenital atrophy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Advanced androgen dependent Prostate cancer, Female castration, Hypoestrogenism
- Associated Therapies
- Contraception, Hormone Replacement Therapy, Palliative Treatment
Estrogen Deficiency on Cardiovascular Risk
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06369363
Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 111
- Registration Number
- NCT06353269
- Locations
- 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
Brain Blood Flow Responses to Stress: Sex Differences
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 26
- Registration Number
- NCT06253702
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Walter Reed National Military Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT06247267
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 90
- Registration Number
- NCT06005610
- Locations
- 🇺🇸
Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States
🇺🇸Houston AIDS Research Team CRS (31473), Houston, Texas, United States
🇺🇸UCSD Antiviral Research Center CRS (701), San Diego, California, United States
The Effect of Sildenafil Citrate on Frozen Embryo Transfer Cycles
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 110
- Registration Number
- NCT05951413
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt
Pharmacological Preparation of the Cervix for Hysteroscopy
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Jagiellonian University
- Target Recruit Count
- 96
- Registration Number
- NCT05783479
- Locations
- 🇵🇱
Jagiellonian University Medical College, Department of Gynecology and Obstetrics, Kraków, Poland
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT05716516
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 1050
- Registration Number
- NCT05617820
- Locations
- 🇺🇸
Site 10135, San Diego, California, United States
🇺🇸Site 10111, Las Vegas, Nevada, United States
🇺🇸Site 10146, Chandler, Arizona, United States
Postpartum Vaginal Estrogen for Breastfeeding Patients
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05457972
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.